This study aims to evaluate the coverage of disease-modifying therapies for multiple sclerosis under Medicare Part D, focusing on brand-name versus generic options.
Cohort study analyzing formulary coverage under Medicare Part D for patients with multiple sclerosis.
Comparison of coverage between brand-name and generic disease-modifying therapies.
Identified significant differences in coverage between brand-name and generic drugs for multiple sclerosis therapies.
Showed variability in formulary access that could impact patient treatment choices.
Resumen
This cohort study examines Medicare Part D formulary coverage of disease-modifying therapies for patients with multiple sclerosis, comparing coverage of brand-name and generic drugs.